In China's largest pivotal trial ever -- 21, 000 people -- Qiagen's TB test showed the incidence of latent TB infection in China's population is 18.8%. That was far lower than the 28.8% indicated by the century-old TB skin test, which registered many false positives. The QuantiFERON-TB Gold (QFT®) test, an interferon-gamma release assay, was approved for use in China in 2013. By lowering the estimate of China's at-risk population, the test renders a TB preventative program more feasible. Qiagen is headquartered in the Netherlands.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
